Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017087 | 1.00 | MAOB (0.55) | MAOBGID4MAOASCN9A | |
| SCHEMBL31061697 | 1.00 | MAOB (0.55) | MAOBGID4MAOASCN9A | |
| SCHEMBL2017091 | 1.00 | MAOB (0.55) | MAOBGID4MAOASCN9A | |
| SCHEMBL7395180 | 0.87 | MAOB (0.54) | MAOBGID4MAOASCN9A | |
| SCHEMBL3061396 | 0.87 | MAOB (0.54) | MAOBGID4MAOASCN9A | |
| SCHEMBL2014885 | 0.86 | MAOB (0.74) | MAOBMAOASCN9A | |
| SCHEMBL31060712 | 0.86 | MAOB (0.74) | MAOBMAOASCN9A | |
| SCHEMBL963815 | 0.86 | MAOB (0.74) | MAOBMAOASCN9A | |
| SCHEMBL8935315 | 0.86 | ALOX5 (0.57) | MAOBGID4MAOASCN9A | |
| SCHEMBL7396992 | 0.86 | BCHE (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160308-A1 | Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders | ALCON RESEARCH, LTD. (US) | 2011-06-30 | — | — | US | disclosed |
| CN-101495185-A | Monoamine oxidase inhibitors for the treatment of disorders of the outer retina | ALCON RES LTD (US) | 2009-07-29 | — | — | CN | disclosed |
| EP-2046451-A1 | MONOAMINE OXIDASE INHIBITORS USEFUL FOR TREATING DISORDERS OF THE OUTER RETINA | Alcon Research, Ltd. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008014457-A1 | MONOAMINE OXIDASE INHIBITORS USEFUL FOR TREATING DISORDERS OF THE OUTER RETINA | ALCON RESEARCH LTD. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-5391577-A | Active on central nervous system; antiepileptic agents | FARMITALIA CARLO ERBA S R L (IT) | 1995-02-21 | — | — | US | disclosed |
| US-5236957-A | Antiepileptic agents | FARMITALIA CARLO ERBA SRL (IT) | 1993-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160308-A1 | Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders | MAOB, MAOA, ALDH1A2 | MAOB 1/4885GID4 1295/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.